title: Disposition of antimony and aminosidine combination after multiple subcutaneous injections in dogs.
abstract: The disposition of a combination of antimony (Sbv) (12.8 mg/kg) and aminosidine (AM) (10 mg/kg) in 10 healthy Beagle dogs after multiple subcutaneous injections is described. Sbvplasma concentrations were determined by atomic absorption spectrometry, and AM by ion-pair liquid chromatography, using a fluorimetric detector. Sbvreached Cmaxat 60 min, and for about 1 h plasma levels were homogeneously stabilized between 10.78 and 11.76 microgram/mL; by 12 h, Sbvplasma concentrations were close to the detection limit (0.3 microgram/mL). AM Cmaxvalues were recorded after 1 h (30.6+/-3.11 microgram/mL, mean +/- SD), and plasma levels reached values close to the detection limit (0.15 microgram/mL) between 7 and 8 h after injection. Sbvkinetic parameters did not appear modified by the presence of AM. Moreover, repeated injections of the combination did not modify the kinetic behaviour of the two drugs and did not alter the renal function of the animals. The superimposition analysis of the Sbvdata suggests that a twice daily injection of the metal at a dose of 12.8 mg/kg would be sufficient to maintain inhibitory Sbvconcentrations similar to those recorded in humans.
mesh_terms: D000563:Amebicides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000818:Animals; D000965:Antimony / Q000097:blood; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002853:Chromatography, Liquid / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy / Q000469:parasitology; D004285:Dogs / Q000378:metabolism*; D004359:Drug Therapy, Combination; D005260:Female; D005470:Fluorometry / Q000662:veterinary; D006207:Half-Life; D007279:Injections, Subcutaneous / Q000662:veterinary; D016018:Least-Squares Analysis; D018314:Leishmania infantum / Q000187:drug effects; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000662:veterinary; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010303:Paromomycin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D013054:Spectrophotometry, Atomic / Q000662:veterinary